Abstract
Systematic SARS-CoV-2 testing is a valuable tool for infection control and surveillance. However, broad application of high sensitive RT-qPCR testing in children is often hampered due to unpleasant sample collection, limited RT-qPCR capacities and high costs. Here, we developed a high-throughput approach (‘Lolli-Method’) for SARS-CoV-2 detection in children, combining non-invasive sample collection with an RT-qPCR-pool testing strategy. SARS-CoV-2 infections were diagnosed with sensitivities of 100% and 93.9% when viral loads were >106 copies/ml and >103 copies/ml in corresponding Naso-/Oropharyngeal-swabs, respectively. For effective application of the Lolli-Method in schools and daycare facilities, SEIR-modeling indicated a preferred frequency of two tests per week. The developed test strategy was implemented in 3,700 schools and 698 daycare facilities in Germany, screening over 800,000 individuals twice per week. In a period of 3 months, 6,364 pool-RT-qPCRs tested positive (0.64%), ranging from 0.05% to 2.61% per week. Notably, infections correlated with local SARS-CoV-2 incidences and with a school social deprivation index. Moreover, in comparison with the alpha variant, statistical modeling revealed a 36.8% increase for multiple (≥2 children) infections per class following infections with the delta variant. We conclude that the Lolli-Method is a powerful tool for SARS-CoV-2 surveillance and infection control in schools and daycare.
Competing Interest Statement
The authors have no competing interests. F.D., F.K. and R.K. hold EU-wide trademark protection for the terms Lolli-Test (018503959) and Lolli-Methode (018503958).
Funding Statement
Funding was provided by the German Ministry of Education and Research (BMBF) (registration number: 01KX2021) within Bundesweites Forschungsnetz Angewandte Surveillance und Testung (B-FAST) project of the NaFoUniMedCovid19 consortium. Furthermore, funding was provided by the state of North Rhine-Westphalia and by the Bundesministerium fuer Bildung und Forschung (registration number: ZMI1-2521COR004).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The prospective validation study was approved by the ethics committee of the Faculty of Medicine and University Hospital of Cologne, Cologne, Germany (number 20-1405) as well as by the ethics committee of the High Specialty Regional, Villahermosa, Mexico (number 0130144). The retrospective analysis of the SARS-CoV-2 screening in schools by the University Hospital of Cologne was engaged by the Ministry of Education and Schools and approved by the ethics committee of the Faculty of Medicine, University Hospital of Cologne, Germany (number 21-1358). For retrospective analysis of the SARS-CoV-2 screening in daycare facilities, the University of Cologne was engaged by the Youth Welfare Office of the city of Cologne and approved by the ethics committee of the Faculty of Medicine, University Hospital of Cologne, Germany (number 21-1358).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
